These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 8894498)

  • 1. Oral antidiabetic drugs: an overview.
    Melander A
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S143-7. PubMed ID: 8894498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.
    Melander A; Bitzén PO; Faber O; Groop L
    Drugs; 1989 Jan; 37(1):58-72. PubMed ID: 2651086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus.
    Jennings PE
    Drugs Aging; 1997 May; 10(5):323-31. PubMed ID: 9143853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihyperglycaemic agents. Drug interactions of clinical importance.
    Scheen AJ; Lefèbvre PJ
    Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug therapy in subjects with impaired glucose tolerance].
    Kawamori R; Yoshii H
    Nihon Rinsho; 1996 Oct; 54(10):2750-3. PubMed ID: 8914439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H; Miller JL; Rose LI
    Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of type 2 diabetes mellitus with special reference to metformin therapy.
    Campbell IW
    Diabete Metab; 1991 May; 17(1 Pt 2):191-6. PubMed ID: 1936475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of antidiabetic medications in overdose.
    Spiller HA
    Drug Saf; 1998 Nov; 19(5):411-24. PubMed ID: 9825953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Acta Clin Belg; 1993; 48(4):259-68. PubMed ID: 8212978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic optimisation of oral hypoglycaemic therapy.
    Marchetti P; Giannarelli R; di Carlo A; Navalesi R
    Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
    Rosak C
    J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
    Lebovitz HE
    Drugs; 1992; 44 Suppl 3():21-8. PubMed ID: 1280574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of sulphonylureas in the management of type 2 diabetes mellitus.
    Rendell M
    Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.